Spyre Therapeutics (SYRE)
91.40
+6.68 (7.88%)
Upcoming Events
Latest Headlines
Spyre Therapeutics presents IBD antibody data at UEGW 2026
October 18, 2026 9:30 AM - StreetInsider
Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
October 18, 2026 9:30 AM - StreetInsider
UBS Starts Spyre (SYRE) at Buy
October 12, 2026 2:17 AM - StreetInsider
Form SCHEDULE 13D/A Spyre Therapeutics, Inc. Filed by: Fairmount Funds Management LLC
October 9, 2026 5:01 PM - SEC Filing
Jefferies reiterates Top Pick on Spyre
October 9, 2026 10:05 AM - StreetInsider
Form 8-K Spyre Therapeutics, Inc. For: Oct 05
October 7, 2026 8:00 AM - SEC Filing
Form 424B5 Spyre Therapeutics, Inc.
October 6, 2026 4:42 PM - SEC Filing
Spyre Therapeutics prices $350M stock offering at $85 per share
October 5, 2026 8:14 PM - StreetInsider
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
October 5, 2026 8:13 PM - Globe NewsWire
Spyre Therapeutics stock falls on public offering launch
October 5, 2026 4:31 PM - StreetInsider
Form 424B5 Spyre Therapeutics, Inc.
October 5, 2026 4:10 PM - SEC Filing
Spyre Therapeutics launches public stock offering on Nasdaq
October 5, 2026 4:01 PM - StreetInsider
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
October 5, 2026 4:01 PM - StreetInsider
Form 4 Spyre Therapeutics, Inc. For: Oct 01 Filed by: King-Jones Heidy
October 2, 2026 9:30 PM - SEC Filing
Form 4 Spyre Therapeutics, Inc. For: Oct 01 Filed by: Turtle Cameron
October 2, 2026 9:30 PM - SEC Filing
Form 4 Spyre Therapeutics, Inc. For: Sep 30 Filed by: Burrows Scott L
October 2, 2026 9:29 PM - SEC Filing
Spyre Therapeutics Announces Grants of Inducement Awards
October 2, 2026 4:05 PM - Globe NewsWire
Form 144 Spyre Therapeutics, Inc. Filed by: Turtle Cameron
October 1, 2026 4:37 PM - SEC Filing
Form 144 Spyre Therapeutics, Inc. Filed by: King-Jones Heidy
October 1, 2026 4:31 PM - SEC Filing
Form SCHEDULE 13G Spyre Therapeutics, Inc. Filed by: Paradigm Biocapital Advisors LP
October 1, 2026 4:06 PM - SEC Filing
JPMorgan Starts Spyre (SYRE) at Overweight
October 1, 2026 2:42 AM - StreetInsider
Form 144 Spyre Therapeutics, Inc. Filed by: Burrows Scott L
September 30, 2026 4:03 PM - SEC Filing
Baird Reiterates Outperform Rating on Spyre (SYRE)
September 9, 2026 5:40 AM - StreetInsider
Spyre's SPY003 meets primary endpoint in Phase 2 UC trial
September 8, 2026 8:04 AM - StreetInsider
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
September 8, 2026 8:00 AM - StreetInsider
Spyre Therapeutics to Participate in Upcoming September Investor Conferences
September 3, 2026 4:05 PM - StreetInsider
Spyre (SYRE) PT Lowered to $116 at Baird
August 27, 2026 6:19 AM - StreetInsider
Guggenheim Reiterates Buy Rating on Spyre (SYRE)
August 27, 2026 2:20 AM - StreetInsider
Spyre (SYRE) Reiterated at Buy by Stifel on Topline Results From RA PoC Sub-Study
August 26, 2026 7:28 AM - StreetInsider
After-Hours Movers: INTU, SMTC, SYRE, ZM, NCNO
August 25, 2026 4:41 PM - StreetInsider
Form 8-K Spyre Therapeutics, Inc. For: Aug 25
August 25, 2026 4:05 PM - SEC Filing
Spyre RA drug trial misses internal bar despite some efficacy
August 25, 2026 4:01 PM - StreetInsider
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
August 25, 2026 4:01 PM - StreetInsider
Form SCHEDULE 13G/A Spyre Therapeutics, Inc. Filed by: PERCEPTIVE ADVISORS LLC
August 14, 2026 5:24 PM - SEC Filing
Form SCHEDULE 13G/A Spyre Therapeutics, Inc. Filed by: RTW INVESTMENTS, LP
August 14, 2026 8:10 AM - SEC Filing
Spyre (SYRE) PT Raised to $140 at Jones Trading
August 12, 2026 9:45 AM - StreetInsider
Form 4 Spyre Therapeutics, Inc. For: Aug 07 Filed by: Albers Jeffrey W.
August 10, 2026 9:32 PM - SEC Filing
Spyre Therapeutics launches SPY772 program and Phase 2 trial in HS
August 10, 2026 8:00 AM - StreetInsider
Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa
August 10, 2026 8:00 AM - StreetInsider
Form 144 Spyre Therapeutics, Inc. Filed by: Albers Jeffrey W.
August 7, 2026 4:40 PM - SEC Filing
Form 144 Spyre Therapeutics, Inc. Filed by: Albers Jeffrey W.
August 7, 2026 4:40 PM - SEC Filing
Spyre Therapeutics Announces Grants of Inducement Awards
August 7, 2026 4:05 PM - Globe NewsWire
Form 4 Spyre Therapeutics, Inc. For: Aug 03 Filed by: Burrows Scott L
August 5, 2026 9:32 PM - SEC Filing
Form 4 Spyre Therapeutics, Inc. For: Aug 03 Filed by: Turtle Cameron
August 5, 2026 9:31 PM - SEC Filing
Spyre (SYRE) PT Raised to $115 at Wells Fargo
August 5, 2026 7:58 AM - StreetInsider
Spyre Therapeutics, Inc. (SYRE) Tops Q2 EPS by 40c
August 4, 2026 5:51 PM - StreetInsider
Form 8-K Spyre Therapeutics, Inc. For: Aug 04
August 4, 2026 4:06 PM - SEC Filing
Form 10-Q Spyre Therapeutics, Inc. For: Jun 30
August 4, 2026 4:03 PM - SEC Filing
Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 4, 2026 4:02 PM - StreetInsider
Form 144 Spyre Therapeutics, Inc. Filed by: Burrows Scott L
August 3, 2026 4:52 PM - SEC Filing
Wolfe Research Downgrades Spyre (SYRE) to Peerperform
July 28, 2026 5:34 AM - StreetInsider
Full Article List
